title: Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study.
abstract: The EQ-5D and SF-6D are 2 health-related quality-of-life indexes that provide preference-weighted measures for use in cost-effectiveness analyses.
  
  
  
  The National Cancer Institute's Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium included the EQ-5D and SF-12v2 in their survey of newly diagnosed lung cancer patients. Utilities were calculated from patient-provided scores for each domain of the EQ-5D or the SF-6D. Utilities were calculated for categories of cancer type, stage, and treatment.
  
  
  
  There were 5015 enrolled lung cancer patients with a baseline survey in CanCORS; 2396 (47.8%) completed the EQ-5D, and 2344 (46.7%) also completed the SF-12v2. The mean (standard deviation) utility from the EQ-5D was 0.78 (0.18), and from the SF-6D (derived from SF-12v2) was 0.68 (0.14). The EQ-5D demonstrated a ceiling effect, with 20% of patients reporting perfect scores, translating to a utility of 1.0. No substantial SF-6D floor effects were noted. Utilities increased with age and decreased with stage and comorbidities. Patient-reported (EQ-5D) visual analog scale scores for health status had a moderate (r = 0.48, p < 0.0001) positive correlation with utilities. A subset (n = 1474) completed follow-up EQ-5D questionnaires 11-13 months after diagnosis. Among these patients, there was a nonsignificant decrease in mean utility for stage IV and an increase in mean utility for stages I, II, and III.
  
  
  
  This study generated a catalog of community-weighted utilities applicable to societal-perspective cost-effectiveness analyses of lung cancer interventions and compared utilities based on the EQ-5D and SF-6D. Potential users of these scores should be aware of the limitations and think carefully about their use in specific studies.
authors: Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA (ACT, MCM, JSS, PMM)
authors: Angela C
authors: AC
authors: Tramontano
authors: Dna-Farber Cancer Institute, Boston, MA (DLS, JCW)|Department of Radiology, Harvard Medical School, Boston, MA (DLS, JSS, PMM).
authors: Deborah L
authors: DL
authors: Schrag
authors: David Geffen School of Medicine at UCLA, Los Angeles, CA (JKM)
authors: Jennifer K
authors: JK
authors: Malin
authors: Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA (ACT, MCM, JSS, PMM)
authors: Melecia C
authors: MC
authors: Miller
authors: Dna-Farber Cancer Institute, Boston, MA (DLS, JCW)
authors: Jane C
authors: JC
authors: Weeks
authors: Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA (ACT, MCM, JSS, PMM)|Department of Radiology, Harvard Medical School, Boston, MA (DLS, JSS, PMM).
authors: J Shannon
authors: JS
authors: Swan
authors: Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA (ACT, MCM, JSS, PMM)|Department of Radiology, Harvard Medical School, Boston, MA (DLS, JSS, PMM).
authors: Pamela M
authors: PM
authors: McMahon
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D015897:Comorbidity; D003362:Cost-Benefit Analysis; D005260:Female; D006304:Health Status; D006801:Humans; D008175:Lung Neoplasms / Q000191:economics* / Q000523:psychology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017063:Outcome Assessment, Health Care; D011594:Psychometrics; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D044469:Racial Groups; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires
keywords: EQ5D; SF6D; lung cancer; quality-of-life; utilities